Le Lézard
Classified in: Health
Subject: FDA

Access Vascular Receives FDA Clearance For Its HydroPICC Catheter


BEDFORD, Mass., Feb. 22, 2018 /PRNewswire/ -- Access Vascular, a medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, announced today that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product, the HydroPICCtm, a peripherally inserted central catheter, intended for long-term use. In pre-clinical testing, the HydroPICC demonstrated a 30x reduction in platelet count when compared with current market-leading PICC.1

Access Vascular is reinventing venous access with devices that leverage our proprietary bulk hydrophilic biomaterial to improve care, decrease complications and reduce costs. Initially focused on launching our HydroPICC device, a peripherally inserted central catheter with superior material performance that will address a critical need for devices that lower thrombotic risk and adverse events, we are in the early stages of developing hemodialysis, implantable ports and drug delivery devices.

"The FDA clearance of the HydroPICC catheter is an important milestone for Access Vascular and a critical step forward on our pathway to commercialization," said James Biggins, founder, president and CEO of Access Vascular Inc. "Today's news is a validation of our team's commitment to innovation and to addressing critical unmet needs in venous access. Our proprietary, unique technology does not flake or elude, and in vitro study results demonstrate our device's ability to reduce thrombus accumulation as compared to currently available technologies. The reduction in thrombosis demonstrated in testing could have a significant and profound impact on the lives of millions of patients."

Venous access devices are ubiquitous within the healthcare system. In the U.S., over 3 million PICCs are placed every year to deliver drugs or nutrition to patients. Along with the benefits comes the significant potential of complications arising from the placement of a long-term catheter into a small caliber peripheral vein with multi-week indwell time. According to one study, 34 percent of PICCs placed will experience complications. 2,3 These potential complications could significantly increase morbidity, hospital stay and overall cost of care.

"The risk of catheter thrombosis is significant and can often trigger a cascade of events leading to further complications," added Dr. Gary M. Ansel, System Medical Chief, Vascular Services, Ohio Health Heart & Vascular Physicians and Access Vascular Medical Advisory Board Member. "The proprietary technology used in HydroPICC addresses many of the issues that arise with current venous access devices. By reducing thrombosis on the catheter, we may be able to lessen the risk of complications associated with blood clots, potentially improve outcomes and lead to improved "valued care" by positively impacting healthcare costs." 

To meet the anticipated demand for the HydroPICC and to advance the development of a robust pipeline of venous access devices, Access Vascular is expanding its manufacturing and testing facility with an additional 4,000-square foot state-of-the-art lab and manufacturing space and growing the commercial and manufacturing teams.

ABOUT ACCESS VASCULAR'S PROPRIETARY BULK-HYDROPHILIC MATERIAL

Unlike current devices made from polyurethane, Access Vascular has developed a proprietary bulk-hydrophilic material that has a high-water content and a neutral surface charge, while meeting the performance needs for a power injectable catheter. These features make it the ideal material for long-term implantable vascular access devices that markedly reduce thrombus accumulation on the devices. The proprietary material had been demonstrated through testing not to initiate the thrombosis cascade and therefore does not trigger the body's thrombotic response.4 

ABOUT ACCESS VASCULAR
Access Vascular is reinventing venous access using our novel bulk-hydrophilic material platform to develop devices that address the key unmet need in the space?reducing catheter thrombus accumulation. Our technology has the potential to improve care, decrease complications and reduce costs by reducing complications resulting from thrombosis. The robust pipeline currently includes midlines, drug delivery catheters, dialysis catheter, and ports, all in various stages of development. More information is available at www.accessvascularinc.com.

1. Data on file at Access Vascular
2. Leroyer, C. et al. Prospective follow-up of complications related to peripherally inserted central catheters. Med. Mal. Infect. 43, 350?355 (2013).
3. Grau, D., Clarivet, B., Lotthé, A., Bommart, S. & Parer, S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob. Resist. Infect. Control 6, 18 (2017).
4. Data on file at Access Vascular

Media Contact:
Helen Shik
Shik Communications LLC
[email protected] 
617-510-4373

SOURCE Access Vascular, Inc.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: